High plasma norepinephrine levels associated with beta2-adrenoceptor polymorphisms predict future renal damage in nonobese normotensive individuals.
Renal injury is common in obesity and hypertension. In the present study, we examined relationships between renal function alterations, plasma norepinephrine (NE), and beta2-adrenoceptor polymorphisms in a longitudinal design over 5 years. In 219 nonobese, normotensive men with entry-normal renal function, we measured serum blood urea nitrogen (BUN), creatinine, creatinine clearance, plasma NE, homeostasis model assessment of insulin resistance (HOMA-IR), body mass index (BMI), total body fat mass, and blood pressure (BP) annually for 5 years. beta2 (Arg16Gly, Gln27Glu)-adrenoceptor polymorphisms were determined. The subjects were stable in body weight and BP (<10%) for 5 years. High plasma NE was defined as > or =mean+1 SD at entry. Thirty-seven subjects had entry-high plasma NE and 182 were entry-normal. Entry-high plasma NE subjects had significantly greater total body fat mass and plasma NE and significantly lower creatinine clearance at entry and throughout the study. Increases in BMI, fat mass, BP, plasma NE, BUN, and creatinine, as well as the reduction in creatinine clearance in the 5 years, were significantly greater in entry-high NE subjects. These subjects had significantly higher frequencies of the Gly16 allele of beta2-adrenoceptor polymorphisms. Throughout the study, subjects carrying the Gly16 allele had higher plasma NE, HOMA-IR, and fat mass, and significantly greater reductions in creatinine clearance. Plasma NE at entry was a determinant variable for changes in BUN, creatinine, and creatinine clearance over the 5-year period in multiple regression analysis. In conclusion, high plasma NE at entry, associated with the Gly16 allele of the beta2-adrenoceptor polymorphisms, predict renal function deterioration (seen in elevations of BUN and creatinine and reduction of creatinine clearance) over a 5-year period accompanying further heightened sympathetic nerve activity and deterioration of insulin resistance.
Human Neurotransmitter Laboratory, Baker Heart Research Institute, Melbourne, Australia. kmasuo@baker.edu.au
Kazuko
K
Masuo
Tomohiro
T
Katsuya
Ken
K
Sugimoto
Hideki
H
Kawaguchi
Hiromi
H
Rakugi
Toshio
T
Ogihara
Michael L
ML
Tuck
D000328:Adult; D000483:Alleles; D019943:Amino Acid Substitution; D001794:Blood Pressure / Q000502:physiology; D001806:Blood Urea Nitrogen; D001835:Body Weight / Q000502:physiology; D003404:Creatinine / Q000097:blood*; D005787:Gene Frequency; D005998:Glycine; D006801:Humans; D007668:Kidney / Q000502:physiology*; D008137:Longitudinal Studies; D008297:Male; D009638:Norepinephrine / Q000097:blood*; D020641:Polymorphism, Single Nucleotide; D018343:Receptors, Adrenergic, beta-2 / Q000235:genetics*; D012044:Regression Analysis; D013564:Sympathetic Nervous System / Q000502:physiology
D018343:Receptors, Adrenergic, beta-2; D003404:Creatinine; D005998:Glycine; D009638:Norepinephrine